PRONOUNCE: Randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer

Ralph G. Zinner, Coleman K. Obasaju, David R. Spigel, Robert W. Weaver, J. Thaddeus Beck, David M. Waterhouse, Manuel R. Modiano, Borys Hrinczenko, Petros G. Nikolinakos, Jingyi Liu, Andrew G. Koustenis, Katherine B. Winfree, Symantha A. Melemed, Susan C. Guba, Waldo I. Ortuzar, Durisala Desaiah, Joseph A. Treat, Ramaswamy Govindan, Helen J. Ross

Research output: Contribution to journal › Article › peer-review

101 Scopus citations

Fingerprint

Dive into the research topics of 'PRONOUNCE: Randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences